Anti-Caspr1 antibodies were first seen in a patient with an acute inflammatory demyelinating polyneuropathy (AIDP)-like presentation and also with a subacute or chronic course similar to chronic inflammatory demyelinating neuropathy with exacerbations during infections. Here, CNTNAP1 is linked to infection.